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Abstract: 
There is a concerted research effort to investigate brain mechanisms 
underlying addiction processes that may predicate the development of new 
compounds for treating addiction. One target is the brain’s opioid system, 
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due to its role in the reinforcing effects of substances of abuse. Substance-
dependent populations have increased numbers of the mu opioid receptor 
(MOR) in fronto-striatal regions that predict drug relapse, and demonstrate 
disturbances in these regions during the processing of non-drug rewards. 
Naltrexone is currently licensed for alcohol and opiate dependence, and 
may remediate such disturbances through the blockade of MORs in fronto-
striatal reward circuitry. Therefore, we examined the potential acute 
modulating effects of naltrexone on the anticipation of, and instrumental 
responding for, non-drug rewards in long-term abstinent alcoholics, 
alcoholic poly substance-dependent individuals and controls using a 
monetary incentive delay (MID) task during a randomized double blind 
placebo controlled fMRI study. We report that the alcoholic poly substance-
dependent group exhibited slower and less accurate instrumental 
responding compared to alcoholics and controls that was less evident after 
acute naltrexone treatment. However, naltrexone treatment was unable to 
remediate disturbances within fronto-striatal regions during reward 
anticipation and “missed” rewards in either substance-dependent group. 
While we have not been able to identify the underlying neural mechanisms 
for improvement observed with naltrexone in the alcoholic poly-substance 
dependent group, we can confirm that both substance-dependent groups 
exhibit substantial neural deficits during an MID task, despite being in 
long-term abstinence. 
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Dear Dr. Nestor:  
 
Manuscript ID AB-12-2015-0322.R2 entitled "Acute naltrexone does not remediate fronto-striatal 
disturbances in alcoholic and alcoholic polysubstance-dependent populations on a monetary 
incentive delay task." which you submitted to Addiction Biology, has been reviewed. The comments 
of the reviewer(s) are included at the bottom of this letter.  
 
The reviewer(s) feel that you have adequately revised your submission, but recommend a few 
remaining minor revisions. Once these are addressed, I will be happy to accept the paper without 
additional outside review.  
 
To revise your manuscript, log into http://mc.manuscriptcentral.com/adb and enter your Author 
Center, where you will find your manuscript title listed under "Manuscripts with Decisions." Under 
"Actions," click on "Create a Revision." Your manuscript number has been appended to denote a 
revision. Please DO NOT upload your revised manuscripts as a new submission.  
 
You will be unable to make your revisions on the originally submitted version of the manuscript. 
Instead, revise your manuscript using a word processing program and save it on your computer. 
Please also highlight the changes to your manuscript within the document by using colored text.  
 
Once the revised manuscript is prepared, you can upload it and submit it through your Author 
Center.  
 
When submitting your revised manuscript, you will be able to respond to the comments made by 
the reviewer(s) in the space provided. You can use this space to document any changes you make to 
the original manuscript. In order to expedite the processing of the revised manuscript, please be as 
specific as possible in your response to the reviewer(s).  
 
IMPORTANT: Your original files are available to you when you upload your revised manuscript. 
Please delete any redundant files before completing the submission.  
 
Because we are trying to facilitate timely publication of manuscripts submitted to Addiction Biology, 
your revised manuscript should be uploaded as soon as possible. If it is not possible for you to 
submit your revision in a reasonable amount of time, we may have to consider your paper as a new 
submission. If you feel that you will be unable to submit your revision within the time allowed please 
contact me to discuss the possibility of extending the revision time.  
 
With the increasing popularity and impact of the journal, we have experienced a marked increase in 
submission of high quality papers. As a result, we now increasingly must base acceptance decisions 
not only on absolute merit, but also on relative priority scores. Nevertheless, the pipeline of 
accepted papers has increased, and with it the lag time from acceptance to publication.  
 
As a result of this, the journal is instituting a word limit on papers of 5000 words (excluding abstract, 
references and figure legends). The maximum number of references is now limited to 50. If 
necessary, we encourage authors to provide additional material as online supporting information. 
Occasionally, when there is need to exceed this limit, editorial approval to do so can be sought, but 
page charges for additional pages will have to be carried by the authors. If, when you receive the 
PDF proof, your paper exceeds 8 pages you will incur a charge of £60GBP per extra page. This will 
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take effect for all papers accepted after 1 March 2011.  
 
Once again, thank you for submitting your manuscript to Addiction Biology and I look forward to 
receiving your revision.  
 
Sincerely,  
Prof. Rainer Spanagel  
Editor Addiction Biology, Addiction Biology  
Rainer.Spanagel@zi-mannheim.de, Christine.Roggenkamp@zi-mannheim.de  
 
Editor Comments to Author:  
 
 
 
Reviewer(s)' Comments to Author:  
 
Reviewer: 2  
 
Comments to the Author  
>>> Please find all new comments in bold below:  
 
________________________________________________________________  
 
Reviewer: 1  
 
Comments to the Author  
The authors did a good job in revising the manuscript, all my issues were sufficiently addressed.  
 
Reviewer: 2  
 
Comments to the Author  
Please find all comment below (in line) as a reply to the different ponts raised:  
 
 
Reviewer(s)' Comments to Author:  
 
 
Reviewer: 1  
Comments to the Author  
The paper by Nestor et al. addresses the role of naltrexone on behavioral and neural correlates of 
monetary reward processing in alcoholic and alcoholic polysubstance-dependent populations. The 
authors found that naltrexone remediates slower and less accurate instrumental responding in 
alcoholic polysubstance-dependent individuals. Moreover, both alcoholic groups showed alterations 
in fronto-striatal regions during reward anticipation, that did not change after naltrexone 
administration. The paper is well written, the methods are sound - I have only some suggestions that 
could improve the present version of the manuscript.  
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Reviewer: Both in the Abstract and in the Introduction I miss a link between naltrexone 
administration and non-drug reward processing, i.e. the construct and mechanism of reward 
processing in the context of alcohol dependence and the opioid system is not very well presented 
and the authors also did not explain why they have chosen non-drug reward processing as 
mechanism of interest in this context. Moreover, these aspects then also needs to be included in the 
Discussion section.  
 
 
Response: We have now done this in the abstract as follows: Substance-dependent populations have 
increased numbers of the mu opioid receptor (MOR) in fronto-striatal regions that predict drug 
relapse, and demonstrate disturbances in these regions during the processing of non-drug rewards. 
Naltrexone is currently licensed for alcohol and opiate dependence, and may remediate such 
disturbances through the blockade of MORs in frontostriatal reward circuitry. And in the 
introduction as follows:  
 
 
Substance abusers, particularly alcoholics, may still be at risk for relapse in longterm abstinence due 
to ongoing and latent disturbances in the brain’s opioid system. Opioid disturbances within DA 
fronto-striatal reward circuitry may confer an ongoing risk for relapse to drug rewards if there is a 
diminished incentive value of, and motivation to procure, non-drug rewards. Naltrexone is currently 
licensed for alcohol dependence, and may remediate these disturbances by restoring some balance 
within key fronto-striatal networks that are critical for optimizing the incentive value and attainment 
of non-drug rewards.  
 
> good  
 
Reviewer: On a behavioral level, the authors assessed percentage accuracy and mean reaction time, 
but did not discuss the (non)findings for these two parameters differently, although they represent 
different indicators of reward processing. This should be included.  
 
 
Response: Response accuracy and reaction time on the MID task are highly negatively correlated - 
the reduced latency to respond to the target increases MID accuracy. The latency torespond on win 
trials is measuring the appetitive incentive motivational aspects of the task, whereas accuracy is 
merely a by product of this motivation. We have explored this further by using a behavioural index 
that specifically reflects a higher relative value for reward incentives during instrumental responding 
(neutral reaction time / win reaction time) – where >1 reflects a higher relative motivational value of 
monetary incentives.  
 
> Please deduce this perspective from the literature.  
 
New Response: Previous reports (see references below) have used this behavioural motivational 
index to show a higher relative value for monetary incentives during instrumental responding, which 
we believe, more closely reflects the contrasts in the incentive value of these conditions computed 
during the functional MRI analyses at the first level.  
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Carter, R. M., Macinnes, J. J., Huettel, S. A., & Adcock, R. A. (2009). Activation in the VTA and nucleus 
accumbens increases in anticipation of both gains and losses. Front Behav Neurosci, 3, 21. doi: 
10.3389/neuro.08.021.2009  
Clithero, J. A., Reeck, C., Carter, R. M., Smith, D. V., & Huettel, S. A. (2011). Nucleus accumbens 
mediates relative motivation for rewards in the absence of choice. Front Hum Neurosci, 5, 87. doi: 
10.3389/fnhum.2011.00087  
Sescousse, G., Li, Y., & Dreher, J. C. (2015). A common currency for the computation of motivational 
values in the human striatum. Soc Cogn Affect Neurosci, 10(4), 467-473. doi: 10.1093/scan/nsu074  
 
Editor >>> Please include these arguments in the manuscript.  
 
Response to editor: We have written this under Other Statistics as follows:  
We also conducted a three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo 
vs. naltrexone) repeated measures ANOVA on an index of the relative motivational value (RMV). This 
value is based on the ratio of mean reaction times to the target on neutral trials compared to that on 
win trials - i.e. RT neutral/RT win. Here a value >1 reflects a higher relative value of monetary 
incentives (Sescousse et al., 2015), and which more closely reflects the contrasts in the incentive 
value of these conditions computed during the functional MRI analyses. 
 
Reviewer: The authors did not provide any information on their ROIs or are their findings based on 
whole brain level?  
 
 
Response: The findings are based on whole brain cluster-based corrected statistics.  
 
> Ok  
 
Reviewer: Last, I was wondering whether the authors have also data on craving of their groups? As 
this is associated with for example reward processing and relapse and frontal and limbic brain 
regions, it might be an interesting factor, at least as control factor.  
 
 
Response: Craving data was collected on each visit. Participants, however, did not report high levels 
of craving during these visits, quite possibly, because they were in long-term abstinence. Craving was 
also difficult to assess in the Alcoholplus group given the multiple substances they had been 
dependent on.  
 
> Please report levels of craving as collected.  
 
New Response: Whilst we did include a questionnaire to collect craving data from participants in the 
ICCAM platform, we do not believe that the craving data is clinically or scientifically meaningful for 
these particular participants for a number of reasons. Firstly, these participants had been abstinent 
for substantial period of time. Secondly, craving was only assessed at one time point - i.e. prior to 
drug administration at each visit. Nevertheless concerning alcohol craving, we found no significant 
differences between the placebo and naltrexone visits (t=0.03; df=20; p=0.98) in the alcohol minus 
group. In the alcoholplus group the range of substances abused makes it hard to interpret craving 
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data. Assessment of craving is something that would need to be carefully considered in any future 
uses of ICCAM platform and tailored specifically to the range of substances used.  
 
Editor >>> Ok, please mention this under limitations.  
Response to editor: We have now written this under limitations as follows: 
Furthermore, we did not thoroughly assess alcohol and drug craving at each session across the 
groups, which may have had a possible influence on our metrics of motivation and reward 
processing. 
 
Reviewer: 2  
Comments to the Author  
This work presents an interesting study exploring the influence of a mu opioid receptor antagonist 
(naltrexone) on reward processing in the brain in two different substance-dependent samples and in 
healthy control subjects. The study presents its aims in a clear and brief way. The authors collected 
data in the framework of a big multi-center study. A total of n=21 patients with alcohol dependence, 
n=25 patients with alcohol and other substances dependence and n=35 healthy control subjects 
were analysed. The used methods are comprehensively described. The results are described in brief. 
Further, the authors discuss their results reflecting selected previous literature in the field. Despite 
the interesting topic of the study, it lacks some very important points: firstly, a-priori hypotheses in 
terms of anatomical regions are not totally clear. Secondary, the manuscript raised some 
methodological issued addressed in detail below. Since the study is based on an interesting sample, 
it might be of interest to combine these results with some more clinical data like symptom severity 
etc. in order to extend and improve the possible interpretations as well as the relevance of the 
results. Further, also some ideas on implications for possible future research based on these results 
would be of interest.  
In detail, the authors should consider the following aspects:  
Reviewer: The author state that the participants were long-term abstinentalcoholics and alcoholic 
poly-substance dependent subjects respectively. How was the mentioned “extended abstinence” 
defined? Since the duration and time course of abstinence might be of interest for alterations in 
receptor density etc. the studied samples should be as homogenous as possible regarding this factor. 
The authors state that participants were abstinent for at least 4 weeks. With a mean duration of 
abstinence of alcohol of about 13 months in both groups the range seems to be very wide. Please 
add the range of abstinence of alcohol to the given demographic variables, as also the duration of 
abstinence (Mean, SD, range) should be given for the other substances used. Did you check for the 
results after dividing the groups in subgroups based on duration of abstinence? And please also 
discuss the influence of this factor on the results.  
 
 
Response: Abstinence was defined by a psychiatrist during the in-person clinical screening session as 
the length of time each participant had been off alcohol without relapsing.  
We have now added the range of alcohol abstinence and the duration and range of abstinence for 
the other substances used in the alcoholplus group to the demographics table (see table 1.).  
We did no attempt to split the groups based on the duration of abstinence. By including groups who 
had achieved a stable period in their own individual abstinence, albeit of varying durations within 
groups, we believed it was more likely that participants would be able to complete the entire ICCAM 
study. Therefore, we believe that any such split would significantly reduce our power to detect any 
main effects in our analyses at a group level.  
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> The argument regarding the inclusion of subjects is not relevant for a post-hoc analysis of the 
influence of duration of abstinence > please check by subgroup analyses or correlational analyses.  
 
New Response: We do not believe that these types of analyses would be adequately powered to 
reveal any significant effects as different participants in the Alcoholplus group, for example, had 
been dependent on different substances, and therefore, abstinent from these substances for 
different durations.  
 
Editor >>> Well, then put this aspect under limitations.  
Response to editor: We have now written this under limitations as follows: 
Moreover, dependence on (and abstinent from) multiple and varying substances of abuse in the 
alcoholplus group underpowered us to statistically examine the influence of these measures on 
indices of motivation and reward processing. 
  
 
 
Reviewer: Since the samples are not balanced, are possible gender effects relevant here?  
 
 
Response: We have no reason to believe that there are any possible gender effects as the groups 
were well matched on gender distribution and did not differ significantly on this variable.  
 
> Possible gender differences in the neurobiology of addiction are not well understood. Thus, unless 
you find your effects in both groups independently, please mention gender as a relevant factor 
under limitations and how you dealt with it.  
New Response: The three groups were statistically balanced for gender, as reported in the results 
section under demographics. Therefore, we had no reason to be concerned about possible gender 
effects on the reported group differences in brain activation. It is our understanding that the 
reviewer is requesting that we conduct the same analyses in just the female participants of each 
group, and then separately, in the male participants. We do not believe that these types of analyses 
would be adequately powered with n values of 7, 4 and 6 females for the control, alcoholminus and 
alcoholplus groups respectively.  
 
Editor >>> It was requested to mention gender as a possible relevant factor and I still recommend 
this for the limitations section.  
Response to editor: We have now written this under limitations as follows: 
While our groups were well matched on the distribution of gender, the small number of females in 
each group did not permit us to examine the influence of gender effects on the neurobiology of 
reward and motivational processes in the two substance-dependent groups. 
 
Reviewer: Since exposure to substances of abuse is highly relevant to the brain structure, did you 
control for brain structural differences in your brain functional analyses?  
 
 
Response: We welcome the comment by the reviewer. As brain structure might be influenced by the 
chronic toxic effects of substances of abuse, which are in turn manifested in the form of functional 
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disturbances, controlling for a possible correlated covariate would not make any sense statistically. 
Therefore, we did not control for structural differences between the groups in our functional 
analyses. We did not explore differences either, as the main objective of the study was to test 
whether functional disturbances in response to non-drug rewards in addiction could be 
pharmacologically modulated/remediated. We had no a priori reason to believe that any structural 
differences could be differentially modulated by naltrexone or placebo when the visits were, on 
average, less than two weeks apart.  
 
> The concrete relationship of brain structural and brain functional changes in the reward circuitry is 
not yet clear. If you have other information on a direct relationship between brain structural and 
functional alterations, please refer to the relevant literature. If your hypothesis is true, the results 
will not be changed by including brain structure as a covariate. Thus, please control for possible 
differences in brain structure and show the results at least in the supplements.  
New Response: We have nothing to add beyond the original response - controlling for a possible 
correlated covariate would not make any sense statistically.  
 
Editor >>> I have nothing to add on the previous reply.  
 
Reviewer: How were subjects selected based on the inclusion/ exclusion criteria? By whom? That 
means who did the assessments to ensure that control subjects had no previous history of substance 
abuse etc. And also the statement on page 5/6 is very vague “... in the opinion of the investigator, 
contradicts participation...”. If different investigators participated in the study how was ensured that 
a similar basis of decision was used?  
 
Response: We welcome the question from the reviewer. Assessments related to inclusion/exclusion 
criteria were conducted in all participants by a psychiatrist during the in-person clinical screening 
session at each site. All psychiatric and substance dependence histories were subsequently reviewed 
by two psychiatrists to ensure uniformity of diagnostic thresholds across sites, and any discrepancies 
arbitrated by a third psychiatrist if required. Eligibility queries were raised at weekly teleconferences 
with clinical representatives from all three sites so that consensus could be reached. We have now 
changed this to: …that, in the opinion of a psychiatrist, contraindicated participation…  
 
> Ok  
 
Reviewer: Since comorbid secondary or lifetime depression and anxiety were permitted, how did 
you check for a possible influence of mood and previous mood or anxiety disorders on brain activity 
(and since it is well known that the reward system is altered in such diseases).  
 
 
Response: We welcome the question from the reviewer. Secondary or lifetime history of depression 
or anxiety was permitted in the substance groups since this is a very common comorbidity in 
substance addiction. Therefore, we have no way of confirming or rejecting the influence of previous 
mood or anxiety disorders on the observed activation differences between the groups as there is no 
statistical technique for reliably achieving this.  
 
> Please use any scale on anxiety or mood you have to use as covariate in order to parcel out this 
variance. Or discuss why you did not use such a scale and add the possible influence of mood/ 
anxiety under limitations.  
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New Response: We have nothing to add beyond the original response - depression or anxiety are 
common comorbidities in substance addiction, and we acknowledge, may be a possible confound. 
There is, however, no currently known statistical technique that can adequately account for such 
confounds, and the use of covariates (e.g., anxiety or mood measures) that are correlated with the 
independent variable (i.e. group) can lead to unpredictable results. Therefore, we do not believe 
that the use of covariates in any of our analyses will provide greater clarity.  
 
Editor >>> I have nothing to add on the previous reply. Please at least reflect on such confounds 
under limitations.  
Response to editor: We have now written this under limitations as follows: 
Limitations of the current study include a lack of complete matching of groups with respect to age, 
cannabis and cigarette use, anxiety and mood measures, which means we cannot unequivocally 
dismiss their potential influence on altered reward processing in fronto-striatal circuitry of both the 
alcoholminus and alcoholplus groups. 
 
 
 
Reviewer: It would also be very helpful to add information on symptom severity etc. This might also 
be a relevant factor explaining group differences.  
 
 
Response: We did not collect measures of symptom severity that went beyond the typical screening 
measures (e.g., structured clinical interview, ASSIST) that were used to classify and include/exclude 
participants. Given that we recruited participants in extended periods of abstinence, we did not 
anticipate recruiting participants who displayed any symptoms of severity of dependence.  
 
> Ok, but you collected craving severity as mentioned before which is one possible parameter…. As 
suggested before, please use this one.  
New Response: Please refer to the new response provided to reviewer number 1 above with respect 
to craving.  
 
Editor >>> see above.  
 
Response to editor (as above):  
Furthermore, we did not thoroughly assess alcohol and drug craving at each session across the 
groups, which may have had a possible influence on our metrics of motivation and reward 
processing. 
 
 
 
Reviewer: The total duration of the MRI session was 90 Minutes. This is a very long session leading 
to various questions related to data quality. Please carefully comment on that.  
 
Response: The total duration of each scan at the placebo and naltrexone experimental visits was 
actually 60 minutes. This involved participants also completing a resting state scan and two other 
tasks. “…or unable to lie still in the MRI scanner for up to 90 minutes…” was used as an exclusion 
criterion as the same participants were required to undergo a longer baseline session (which also 
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included structural and DTI measures) to acclimatize them to the scanning environment. We have 
had no issues on the MID task (e.g., movement, performance) that have raised any questions across 
the three sites with respect to data quality.  
 
> Please comment on the acting you took in order to ensure data quality, i.e. did you use movement 
parameters as covariates on fist level?  
New Response: We did introduce movement parameters into the first level analyses in FSL FEAT. We 
have now stated this in the methods section under MID fMRI data analyses: as follows  
 
The six rigid body movement parameters were also included as regressors in the model in FSL FEAT.  
 
Editor >>> Ok 
  
Reviewer: To improve clarity, please explicitly state the used study design.  
 
Response: The study used a randomized double blind placebo controlled design.  
 
> Yes, please state in the manuscript under methods.  
New Response: We have inserted this into the manuscript under participants in the Materials and 
Methods section as follows:  
This was a randomized double blind placebo controlled multi-centre study involving three study sites 
in the United Kingdom (Imperial College, Cambridge and Manchester - ICCAM).  
 
Editor >>> Ok  
 
Reviewer: How much did they get paid and when? And how did they get the won money from the 
MID task? If relevant, please also comment on the possible influence on brain activity.  
Response: Participants were paid for their time. For the first in-person clinical assessment visit, 
participants were immediately paid £50. They were then paid £50 for each subsequent experimental 
visit, which they received upon completion of the study. Participants could win up to £18 across the 
two runs of the MID task. Trial parameters were adjusted, however, to ensure approximately 66% 
success rate, leaving the chance to win approximately £12 total. This money was also paid to 
participants up completion of the study.  
 
> Relevant for brain activation is the specific instruction/ money shown before the experiment etc., 
please add this information on the design.  
New Response: The money they could win was not shown to them before they completed the MID 
task in the scanner.  
 
Editor >>> Anyway, the money could have been shown to them before entering the scanner since 
this increases the neural response…  
 
Response to editor: Indeed some studies have employed this procedure using the MID task, which 
may well have enhanced their motivation to do well on the task, and the neural response to the 
anticipation of winning money. Unfortunately, we did not employ this procedure on ICCAM.  
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Reviewer: How did the authors deal with the multi-center setting in general (quality control etc.) and 
with the fact that different MR scanners were used in particular?  
 
 
Response: Acquisition parameters for the EPI sequences were used to create images with 
characteristics as similar as possible. We also used existing sequences specifically designed to reduce 
inter-scanner variance. For instance, at Manchester (Philips scanner) fewer EPI slices were collected, 
so that the data could be made as similar as possible (while remaining within SAR limits) in quality 
when compared with the Siemens scanners at the Cambridge and London sites. No task was 
observed to have significant differences between sites at the whole brain level when balanced 
groups of healthy controls were observed during their baseline session. Between centre issues are 
investigated in McGonigle et al., The ICCAM platform study: An experimentalmedicine platform for 
evaluating new drugs for relapse prevention in addiction. Part B: fMRI description, Journal of 
Psychopharmacology, in submission.  
 
> Please refer to the publication or the relevant data in the manuscript.  
New Response: The manuscript is currently still under review.  
 
Editor >>> Ok, then the necessary information has to be available somewhere. Supplements?  
 
Response to editor: 
All centres operated MRI machines with a main magnetic field of 3 tesla (T). Centres in London and 
Cambridge operated nominally identical 3T Siemens Tim Trio systems running the syngo MR B17 
software with a Siemens 32 channel receive-only phased-array head coil. The Manchester centre 
operated a 3T Philips Achieva running version 2.6.3.5 software and an 8 element SENSE head coil. At 
each visit the imaging session consisted of: localiser scans to set up the positioning of those that 
would follow; main magnetic field mapping, and two runs of the monetary incentive delay task. 
Structural Acquisition 
At London and Cambridge (Siemens), high-resolution T1-weighted volumes were acquired using a 
magnetization-prepared rapid gradient echo (MPRAGE) sequence (TR = 2300 ms, TE = 2.98 ms, TI = 
900 ms, flip angle = 9°, field of view = 256 mm, image matrix = 240 x 256) with a resolution of 1 mm 
isotropic. For the volume, 160 abutting straight sagittal slices were collected in an interleaved right 
to left manner, resulting in whole head coverage. Parallel imaging using Generalized Autocalibrating 
Partially Parallel Acquisition (GRAPPA) with an acceleration factor of 2 was performed. 
At Manchester (Philips), high-resolution T1-weighted volumes were also acquired using an MPRAGE 
sequence (TR = 6.8 ms, TE = 3.1 ms, TI = 900 ms, flip angle = 9°, field of view = 270 mm, image matrix 
= 256 x 256) with an in-plane resolution of 1.055 x 1.055 mm and a slice thickness of 1.200 mm. For 
the volume, 126 abutting straight sagittal slices were collected in an interleaved right to left manner, 
resulting in whole head coverage. Parallel imaging using Sensitivity Encoding (SENSE) with an S 
reduction of 1.8 was performed. 
These T1-weighted volumes followed ADNI protocols to minimise inter-centre differences. 
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Functional Acquisition 
At London and Cambridge (Siemens), functional imaging was performed using a multi-echo gradient 
echo echoplanar imaging (EPI) sequence (TR = 2000 ms, TE = 13 & 31 ms, flip angle = 80°, field of 
view = 225 mm, image matrix = 64 x 64) with an in-plane resolution of 3.516 x 3.516 mm and a slice 
thickness of 3.000 mm. The phase encoding direction was anterior to posterior. Echo spacing was 
0.52 ms. 
For each volume, 36 abutting oblique axial slices were collected in an ascending manner at an angle 
of around 30° to the anterior (AC) and posterior commissure (PC) line. This results in slightly less 
than whole brain coverage, with the most superior 9 mm not being imaged in most participants. 
To achieve the desired resolution and repetition time, parallel imaging using GRAPPA with an 
acceleration factor of 2 was performed. The first three volumes of each functional run were 
automatically discarded to allow for T1 saturation effects and are not included in any number of 
volumes reported here. 
At Manchester (Philips) identical parameters were used for EPI acquisition, but with 34 slices being 
collected and with acceleration achieved using SENSE. 
 
Reviewer: Although loss processing might also be altered in these samples and might therefore be 
relevant for interpreting the results, the authors decided to focus on gain. Please base this decision 
on the literature including latest publications. And please comment on this under limitations.  
Response: While exploring the neural substrates of loss processing we believe is certainly relevant to 
addiction, the primary objective to examine the neural correlates of reward (gain) processing, was 
largely driven by the need to keep scanning time during experimental visits to 60 minutes. We have 
now discussed this as a limitation in the discussion as follows:  
The reduced number of loss trials in our MID task also meant we were unable to examine the neural 
correlates of loss anticipation and outcome, where sensitivity to punishment may well have 
implications for treatment and drug relapse.  
 
> Ok  
 
Reviewer: I strongly recommend integrating the results on outcome processing in the manuscript, 
since the results of a cohesive experiment should be analyses and discussed as a whole and not be 
published in a separated way (see statement on page 9).  
Response: We have now included the results of these analyses in the manuscript in the results 
section as follows: The same whole brain cluster-based repeated measures ANOVA analysis also 
revealed a significant main effect of group for the win miss>neutral miss contrast in the left insula 
(140 voxels; x=-42; y=14; z=-12; zF=3.72; df=1, 79; p<0.001) and the right ACC (415 voxels; x=4; y=44; 
z=4; zF=3.51; df=1, 79; p<0.001) only. As with the anticipation contrast, we additionally conducted 
the same three by two repeated measures ANOVA on the mean BOLD signal change within these 
two clusters. There was a significant effect of group in the left insula (F=4.51; df=2, 78; p<0.05 - 
alcoholminus and alcoholplusneutral hit contrast.  
 
 
We have also discussed these findings as follows: We also observed that the alcoholminus and 
alcoholplus groups exhibited reduced activation changes compared with controls in the anterior 
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insula, and notably, the rostral ACC (rACC) during “missed” rewards. The rACC has been labelled as 
the “affective division” of the cingulate (Bush et al., 2000; Devinsky et al., 1995), through processing 
the emotional components of errors (Luu et al., 2003; van Veen et al., 2002). The observed decrease 
in error-related rACC and insula activation may have resulted from decreases in arousal during 
misses, an effect that was apparently exacerbated by acute opioid blockade with naltrexone. This 
blunting of error-related signalling by naltrexone in substance abusers may have clinical implications, 
where arousal and conflict monitoring are necessary responses to violations in prediction that 
require adjustments to ongoing behaviour during treatment. The effects of naltrexone in the insula 
and ACC, however, may encourage further investigations regarding the effects of opioid blockade on 
error-related neural responses in addiction populations.  
 
> Ok  
 
Reviewer: Why were the two patients groups combined for the analysis of the functional data (see 
page 10)?  
Response: We welcome the question from the reviewer. We initially conducted three (Group: 
alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo vs. naltrexone) whole brain cluster-
based repeated measures ANOVA analyses on the win anticipation>neutral anticipation, win 
hit>neutral hit and win miss>neutral miss contrasts in FSL. We did not observe any group x drug 
interactions, however, leading us to collapse across the two substance groups in order to increase 
the power to find clusters related to a main effect of group in FSL. Following the definition of group 
effect clusters in FSL, we then performed three (Group: alcoholminus vs. alcoholplus vs. control) by 
two (Drug: placebo vs. naltrexone) repeated measures ANOVA analyses on the mean BOLD signal 
change within each of the group ANOVA zF-statistic clusters in SPSS. This was done in order to reveal 
whether the alcoholminus andalcoholplus groups independently contributed to the main ANOVA 
group effect.  
 
> Please state this clearly in the manuscript.  
New Response: This is written in the Functional MRI results section of the manuscript as follows:  
As we did not observe any significant group x drug interactions for a three (Group: alcoholminus vs. 
alcoholplus vs. control) by two (Drug: placebo vs. naltrexone) whole brain cluster-based repeated 
measures ANOVA, we decided to collapse across the two substance groups in order to increase the 
power to detect clusters related to a main effect of group.  
 
>>> Ok  
 
 
Reviewer: What kind of matching was used to parallelize the study groups? Since the authors state 
that the groups differed with regard to various variables including age, years of education, IQ etc. 
these are variables which should be controlled statistically. At least, the influence of these 
systematic differences between groups has to be discussed.  
 
 
Response: We did not use any specific matching to parallelize study groups, which may have led to 
the observed demographic differences reported in the manuscript. The observed group differences 
in performance and BOLD signal, we acknowledge, may have been influenced by certain 
demographic variables (e.g., smoking and cannabis use). While these variables are likely to be 
correlated with the independent variable of group, we have briefly discussed their potential 
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influence as a limitation to interpreting the results. This has been written in the discussion as 
follows:  
 
Limitations of the current study include a lack of complete matching of groups with respect to 
cannabis and cigarette use which means we cannot unequivocally dismiss their potential influence 
on altered reward processing in fronto-striatal circuitry of the alcoholminus, and particularly, the 
alcoholplus groups.  
 
> And what is about the other variables? Please include them in the limitations or argue, why i.e. age 
has no influence on reward processing.  
New Response: Although the alcoholplus were the youngest group, and showed the greatest 
disturbances in frontostriatal activation, we have amended this under the Limitations text as follows:  
Limitations of the current study include a lack of complete matching of groups with respect to age, 
cannabis and cigarette use which means we cannot unequivocally dismiss their potential influence 
on altered reward processing in fronto-striatal circuitry of both the alcoholminus and alcoholplus 
groups.  
 
Editor >>> Ok  
 
Reviewer: Please also state if any covariates of no interest were used.  
 
 
Response: Strong correlations between covariates and independent variables, we believe, should be 
avoided. There is currently no known statistical technique that can adequately account for such 
confounds, and the use of covariates (e.g., smoking, cannabis use) correlated with the independent 
variable (in this case, group) can lead to unpredictable results. Therefore, we did not use covariates 
in any of our analyses.  
 
> If this is your perspective you should deduce it from the literature and comment on it under 
limitations. AND, you should best as possible match the groups!  
 
New Response: We have nothing to add beyond the original response - strong correlations between 
covariates and independent variables, we believe, should be avoided.  
 
Editor >>> Nothing to add to my previous comment.  
 
Reviewer: It does not become clear, why the RMV was used, since no specific hypotheses were 
mentioned in the introduction.  
 
 
Response: The RMV index was used as it more closely reflects, on a behavioural level, the contrast in 
the incentive value of the win and neutral conditions, which is similarly computed during the 
functional analyses with the win>neutral contrasts.  
 
> Ok, please clearly state this in the manuscript.  
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New Response: We have written this under Other Statistics as follows:  
We also conducted a three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo 
vs. naltrexone) repeated measures ANOVA on an index of the relative motivational value (RMV). This 
value is based on the ratio of mean reaction times to the target on neutral trials compared to that on 
win trials - i.e. RT neutral/RT win. Here a value >1 reflects a higher relative value of monetary 
incentives (Sescousse et al., 2015), and which more closely reflects the contrasts in the incentive 
value of these conditions computed during the functional MRI analyses. 
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Abstract 
There is a concerted research effort to investigate brain mechanisms underlying 
addiction processes that may predicate the development of new compounds for 
treating addiction. One target is the brain’s opioid system, due to its role in the 
reinforcing effects of substances of abuse. Substance-dependent populations 
have increased numbers of the mu opioid receptor (MOR) in fronto-striatal 
regions that predict drug relapse, and demonstrate disturbances in these regions 
during the processing of non-drug rewards. Naltrexone is currently licensed for 
alcohol and opiate dependence, and may remediate such disturbances through 
the blockade of MORs in fronto-striatal reward circuitry. Therefore, we examined 
the potential acute modulating effects of naltrexone on the anticipation of, and 
instrumental responding for, non-drug rewards in long-term abstinent alcoholics, 
alcoholic poly substance-dependent individuals and controls using a monetary 
incentive delay (MID) task during a randomized double blind placebo controlled 
fMRI study. We report that the alcoholic poly substance-dependent group 
exhibited slower and less accurate instrumental responding compared to 
alcoholics and controls that was less evident after acute naltrexone treatment. 
However, naltrexone treatment was unable to remediate disturbances within 
fronto-striatal regions during reward anticipation and “missed” rewards in either 
substance-dependent group. While we have not been able to identify the 
underlying neural mechanisms for improvement observed with naltrexone in the 
alcoholic poly-substance dependent group, we can confirm that both substance-
dependent groups exhibit substantial neural deficits during an MID task, despite 
being in long-term abstinence. 
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Introduction 
 Substance dependence, particularly to alcohol, continues to be a major 
cause of harm to individuals and society (Nutt et al., 2010). Identifying the 
substrates of addiction in an attempt to elucidate potential neural targets for 
future treatment development in substance dependence remains a major 
challenge in neuroscience. One such neural target is the brain’s opioid system, 
given its interactions with the dopamine (DA) system of the brain (Solinas et al., 
2004), and its role in the reinforcing effects of alcohol and other substances of 
abuse (Colasanti et al., 2012; Mick et al., 2014; Spreckelmeyer et al., 2011).  
 
Mu opioid receptor (MOR) numbers are reported to be significantly 
elevated in alcoholic patients in early abstinence (Heinz et al., 2005), particularly 
in the ventral striatum (VS), with increased MOR availability found to correlate 
with alcohol craving (Williams et al., 2009). Similarly, cocaine abusers in early 
abstinence have increased numbers of MORs within fronto-striatal regions 
(Gorelick et al., 2005), which have been found to predict relapse (Gorelick et al., 
2008). A similar pattern has been reported in opiate abstinence (Williams et al., 
2007; Zubieta et al., 2000). There is also good evidence that MOR blockade is 
effective in promoting substance abstinence (Grassi et al., 2007; Krystal et al., 
2001; Srisurapanont et al., 2005). Therefore, disturbances to the brain’s opioid 
system during early abstinence make it a viable target for protection against 
potential alcohol and drug relapse. 
 
Substance abusers, particularly alcoholics, may still be at risk for relapse 
in long-term abstinence due to ongoing and latent disturbances in the brain’s 
opioid system. Opioid disturbances within DA fronto-striatal reward circuitry may 
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confer an ongoing risk for relapse to drug rewards if there is a diminished 
incentive value of, and motivation to procure, non-drug rewards. Naltrexone is 
currently licensed for alcohol dependence, and may remediate these 
disturbances by restoring some balance within key fronto-striatal networks that 
are critical for optimizing the incentive value and attainment of non-drug 
rewards.  The current study, therefore, investigated the effects of acute MOR 
blockade with naltrexone on fronto-striatal-dependent reward processing in 
alcoholics and polysubstance-dependent individuals who were in extended 
abstinence. We hypothesized that 1) alcoholic and polysubstance-dependent 
groups, compared to controls, would demonstrate disturbances within fronto-
striatal regions in response to the prediction of potential non-drug rewards and 
2) acute MOR blockade with naltrexone would have an ameliorating effect on 
these neural disturbances, possibly providing a credible therapeutic biomarker 
for treating deficiencies in non-drug reward processing that may trigger relapse 
to addictive behaviour.    
    
Material and Methods 
Participants 
This was a randomized double blind placebo controlled multi-centre study 
involving three study sites in the United Kingdom (Imperial College, Cambridge 
and Manchester - ICCAM). For a more detailed description of the ICCAM 
Platform, see Paterson et al (Paterson et al., 2015).  Inclusion criteria were 
individuals who met DSM-IV criteria for current or prior alcohol dependence 
(Alcoholminus), or alcohol plus (Alcoholplus) another substance of dependence 
(e.g., amphetamines, benzodiazepines, cocaine, opiates) and who would be 
abstinent for at least 4 weeks prior to the experimental sessions. There was no 
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upper limit for abstinence length. All participants were aged 21 to 64. In the 
current study, the Alcoholminus group was made up of 21 abstinent alcoholics, 
with the Alcoholplus group comprised of 25 abstinent alcoholic polysubstance-
dependent individuals (having met criteria for dependence to alcohol plus one or 
more other substances of dependence). The Alcoholplus group was made up of 6 
abstinent alcoholics with cocaine dependence; 6 with cocaine and opiate 
dependence; 4 with amphetamine, cocaine and opiate dependence; 2 with just 
opiate dependence; 1 with amphetamine, cocaine and solvent dependence; 1 
with benzodiazepine, cocaine and opiate dependence; 1 with cocaine and GHB 
dependence; 1 with benzodiazepine and opiate dependence; 1 with 
amphetamine and cocaine dependence; 1 with benzodiazepine and cocaine 
dependence, and 1 with just amphetamine dependence. The healthy control 
group was made up of 35 participants with no previous history of substance 
abuse, as assessed using the ASSIST and timeline follow-back. All participants 
were required to provide a negative breath alcohol test and a negative urine 
sample for various drugs of abuse on both experimental days (screening for the 
presence of amphetamines, benzodiazepines, cannabinoids, cocaine and 
opiates). 
 
Exclusion criteria included 1) current use of regular prescription or non-
prescription medication that could not be stopped for the study duration, or 
would interfere with study integrity or subject safety (including but not limited to 
antipsychotics, anticonvulsants, antidepressants, disulfiram, acamprosate, 
naltrexone, varenicline);  2) current primary axis I diagnosis, past history of 
psychosis (unless drug-induced); 3) current or past history of enduring severe 
mental illness (e.g., schizophrenia, bipolar affective disorder); 4) other current 
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or past psychiatric history that, in the opinion of a psychiatrist, contraindicated 
participation; 5) history or presence of a significant neurological diagnosis that 
may have influenced the outcome or analysis of the results (including but not 
limited to stroke, epilepsy, space occupying lesions, multiple sclerosis, 
Parkinson's disease, vascular dementia, transient ischemic attack, clinically 
significant head injury);  6) claustrophobia or unable to lie still in the MRI 
scanner for up to 90 minutes; 7) presence of a cardiac pacemaker, other 
electronic device or other MRI contraindication, including pregnancy, as assessed 
by a standard pre-MRI questionnaire. Secondary or lifetime history of depression 
or anxiety was permitted in both substance abusers and healthy controls since 
these are very common psychiatric disorders. 
 
Experimental visits 
At the randomised placebo and naltrexone experimental visits, an 
eligibility check was performed. Participants’ intervening drug use and 
concomitant medication were checked and participants completed alcohol 
breath, pregnancy and urine drugs of abuse screening tests. Cigarette smokers 
in all groups smoked ad lib approximately 60 minutes prior to scanning in order 
to avoid the potential confounds of withdrawal and/or craving during scanning.  
 
Medications 
 Drug preparation, labelling and packaging was performed by UCLH 
Pharmacy Manufacturing Unit. Placebo was Vitamin C (100mg, supplier: Sigma, 
manufacturer: Norbrook) and naltrexone (50mg Nalorex® - manufacturer - 
Bristol-Myers Squibb) were prepared and packaged according to Investigational 
Medicinal Product guidelines. The maximum naltrexone plasma concentration 
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after an acute 50 mg dose is 0.5-3 hours (Meyer et al., 1984). Therefore, 
participants were dosed two hours prior to each experimental scan session to 
ensure high MOR occupancy during testing. Naltrexone and placebo medications 
were supplied in identical white opaque bottles and administered by independent 
nursing staff, such that both researcher and participant remained blinded. 
 
Monetary Incentive Delay Task (MID) 
We used a “monetary incentive delay task” (MID), which was based on 
that originally employed by Knutson (Knutson et al., 2001). While being scanned 
on the placebo and naltrexone experimental sessions, participants performed the 
MID task, during which they anticipated potential monetary gain, loss or no 
potential monetary outcome. During each trial, participants viewed one of three 
symbols (a cue) that indicated the potential to win fifty pence (square containing 
an ascending arrow), lose fifty pence (square containing a descending arrow) or 
experience no financial outcome (square containing a horizontal line - here 
referred to as a neutral trial). Each cue was presented for one second, with a 
variable duration (2-4 sec) for the subsequent anticipation period. Following the 
anticipation period, participants made a button press response upon the 
presentation of a visual target (star located within a circle). Following their 
response to the visual target, participants received feedback (1500 ms) as to 
whether they were successful or unsuccessful (“Hit” or “Miss” respectively) on 
each trial, and also saw a running total of their winnings up to that point in the 
task. Following the feedback, there was an end fixation period (3-5 sec) before 
the commencement of the next trial.  
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Because the primary objective of this study was to examine the neural 
correlates of reward processing, we chose to use a smaller number of loss trials 
in an attempt to increase the incentive salience of win trials during the task. 
Consequently, there were a total of 18 “win”, 6 “lose” and 18 “neutral” trials on 
each run of the task. The MID task was additionally tailored to adapt to the 
visual target reaction time of each participant by using a staircase algorithm, 
such that the presentation of the visual target became shorter as performance 
improved during the experiment. This staircase algorithm enabled us to set a 
limit on the success rate of each participant (~66%), which additionally served 
to incentivize participants to engage in the task. Participants were instructed to 
maximize their winnings and were told they would receive them at the end of 
the study. Dependent measures were percentage accuracy and mean reaction 
time (milliseconds) to the visual target on each of the MID trials. There were two 
functional MRI runs of the task (432 s conds each). The task was programmed 
using E-Prime version 2.0 (Psychology Software Tools, Pittsburgh, USA).  
 
Functional MRI (fMRI) Data Acquisition  
 All centres operated MRI machines with a main magnetic field of 3 tesla 
(T). Centres in London and Cambridge operated nominally identical 3T Siemens 
Tim Trio systems running the syngo MR B17 software with a Siemens 32 channel 
receive-only phased-array head coil. The Manchester centre operated a 3T 
Philips Achieva running version 2.6.3.5 software and an 8 element SENSE head 
coil. For anatomical images, 160 high-resolution T1-weighted anatomic MPRAGE 
axial images (FOV 256 mm, thickness 1.0 mm, voxel size 1.0×1.0×1.0) were 
acquired (total duration 303 s). Functional data were acquired using a T2* 
weighted echo-planar imaging sequence collecting 36 non-contiguous (0% gap) 
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3.0 mm axial slices covering the entire brain (TE=31 ms, TR=2000 ms, FOV 225 
mm, 64×64 mm matrix size in Fourier space). The two runs of the MID task 
produced a total of 432 volumes of functional MRI data. 
 
MID fMRI data analyses 
Data pre-processing and statistical analysis were conducted using FEAT 
(fMRI Expert Analysis Tool) from the FMRIB Software Library 
(www.fmrib.ox.ac.uk/fsl). Pre-statistical processing was as follows: motion 
correction utilizing FMRIB’s Linear Image Registration Tool (MCFLIRT; non-brain 
matter removal using Brain Extraction Tool (BET); spatial smoothing with a 5-
mm full-width half maximum Gaussian kernel; mean-based intensity 
normalization; nonlinear high-pass temporal filtering (Gaussian-weighted least 
squares straight line fit, with sigma = 25.0 sec). The six rigid body movement 
parameters were also included as regressors in the model in FSL FEAT.  
For each participant, first level whole-brain mixed-effects analyses were 
performed by modelling the MID anticipation periods (i.e. Neutral, Win) as 
explanatory variables within the context of the general linear model on a voxel-
by-voxel basis (variable boxcar functions for the cue + variable anticipation 
period regressors were convolved with the haemodynamic response function). 
The win and neutral outcome periods (“Hit” and “Miss”) were also modelled 
(stick functions for “hit” and “miss” trial period regressors were convolved with 
the haemodynamic response function). During these first level analyses, the win 
anticipation>neutral anticipation, win hit>neutral hit and win miss>neutral miss 
contrasts was formulated. Owing to the small number of loss trials in the current 
task, the loss cue + anticipation and outcome periods were regressed out of the 
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functional time series as conditions of no interest. The end fixation period of the 
task served as the implicit baseline. Registration was conducted through a two-
step procedure, whereby EPI images were first registered to the high-resolution 
T1 structural image, then into standard (Montreal Neurological Institute, MNI 
avg152 template) space, with 12-parameter affine transformations.  
Two (Group: alcoholminus & alcoholplus combined vs. control) by two (Drug: 
placebo vs. naltrexone) whole brain cluster-based repeated measures ANOVA 
analyses were performed as part of a higher-level mixed-effects analysis on the 
win anticipation>neutral anticipation, win hit>neutral hit and win miss>neutral 
miss contrasts. These higher-level analyses were conducted using FLAME 
(FMRIB's Local Analysis of Mixed Effects). Cluster (Gaussianised F) statistical 
images were determined by Z>2.3 with a corrected cluster significance threshold 
of p<0.05. This ANOVA analysis produced a total of three (i.e. drug effect, group 
effect, drug x group interaction) zF statistical images.  
 
Other Statistics 
 Between groups demographics (see Table 1.) were examined using 
Kruskal–Wallis (gender distribution and drug order) or one-way ANOVA analyses. 
For analyses conducted on the MID behavioural data, we used a three (Group: 
alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo vs. naltrexone) by 
two (Condition: neutral vs. win) repeated measures ANOVA analyses. We also 
conducted a three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) repeated measures ANOVA on an index of the relative 
motivational value (RMV). This value is based on the ratio of mean reaction 
times to the target on neutral trials compared to that on win trials - i.e. RT 
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neutral/RT win. Here a value >1 reflects a higher relative value of monetary 
incentives (Sescousse et al., 2015), and which more closely reflects the 
contrasts in the incentive value of these conditions computed during the 
functional MRI analyses. We extracted the mean BOLD signal change from the 
group zF-statistic ANOVA clusters and conducted three (Group: alcoholminus vs. 
alcoholplus vs. control) by two (Drug: placebo vs. naltrexone) repeated measures 
ANOVA analyses to explore the direction of the effects observed in the cluster-
based analyses. All analyses were conducted using the Statistical Package for 
the Social Sciences (SPSS Inc., Chicago). 
 
Results 
Demographics 
Table 1 shows the between group demographics for the control, 
alcoholminus and alcoholplus groups. The groups significantly differed on most of 
the measures reported herein, including age (alcoholminus>alcoholplus & control), 
years of education (alcoholplus<control), IQ (alcoholplus<control), alcohol 
exposure (control & alcoholplus<alcoholminus), and cigarette (alcoholplus>control) 
and cannabis (alcoholplus>alcoholminus & control) use history. The groups did not 
differ on handedness score or gender distribution. We further report that the 
groups did not differ significantly on drug treatment order (χ2 = 0.48, df=2, p> 
0.7) during the study.  
 
-Insert Table 1 about here- 
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MID Performance 
 Figure 1A below shows the mean MID accuracy (%) for the two conditions 
in the alcoholminus, alcoholplus and control groups during the placebo and 
naltrexone sessions. A three (Group: alcoholminus vs. alcoholplus vs. control) by 
two (Drug: placebo vs. naltrexone) by two (Condition: neutral vs. win) repeated 
measures ANOVA showed a significant effect of condition (F=46.3; df=1, 78; 
p<0.001 - win>neutral) and a significant drug x group interaction (F=4.04; 
df=2, 78; p<0.05). Follow-up analyses revealed that, across MID conditions, the 
alcoholplus group was significantly less accurate than both the alcoholminus 
(p<0.001) and control (p<0.01) groups during the placebo session only. Figure 
1B below shows the mean MID reaction time (milliseconds) for the two 
conditions. The same ANOVA demonstrated a significant effect of condition 
(F=63.6; df=1, 78; p<0.001 - win<neutral) and a significant drug x group 
interaction (F=4.07; df=2, 78; p<0.05). Follow-up analyses revealed that, 
across MID conditions, the alcoholplus group was significantly slower than both 
the alcoholminus and controls groups (p<0.05) during the placebo session only. 
Finally, figure 1C shows the computed index of the RMV. A three (Group: 
alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo vs. naltrexone) 
repeated measures ANOVA showed no effect of drug (F=0.61; df=1, 78; 
p=0.43), group (F=0.45; df=2, 78; p=0.63) or a drug x group interaction 
(F=0.62; df=2, 78; p=0.53) on this index, however.   
 
-Insert Figure 1 about here- 
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Functional MRI 
 All three groups demonstrated statistically significant activation patterns 
across fronto-striatal regions during the placebo and naltrexone challenges for 
the win anticipation>neutral anticipation contrast at a whole brain level (see 
Supplementary Figs 1 & 2). As we did not observe any significant group x drug 
interactions for a three (Group: alcoholminus vs. alcoholplus vs. control) by two 
(Drug: placebo vs. naltrexone) whole brain cluster-based repeated measures 
ANOVA, we decided to collapse across the two substance groups in order to 
increase the power to detect clusters related to a main effect of group. The two 
(Group: alcoholminus & alcoholplus combined vs. control) by two (Drug: placebo vs. 
naltrexone) whole brain cluster-based repeated measures ANOVA analyses 
showed a significant main effect for group (see Supplementary Fig 3), but did 
not reveal a significant main effect for drug or a drug x group interaction. Table 
2 shows the cluster-based statistics from this ANOVA group effect, which 
comprised 12 separate clusters covering cerebellar, occipital, temporal, frontal 
and striatal regions. 
 
-Insert Table 2 about here- 
 
In order to assess the direction of the observed group effect, we performed 
three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo vs. 
naltrexone) repeated measures ANOVA analyses on the mean BOLD signal 
change within each of the group ANOVA zF-statistic clusters. These were 
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performed in order to reveal whether the alcoholminus and alcoholplus groups 
independently contributed to the main ANOVA group effect.  
In the left orbitofrontal cortex (OFC) cluster, there was a main effect of 
group (F=5.25; df=2, 78; p<0.01), which revealed that only the alcoholplus 
group was significantly lower than the control group (p<0.01- Fig 2A) in this 
region. Within the right inferior frontal gyrus (IFG)/insula cluster, however, a 
main effect of group (F=4.25; df=2, 78; p<0.05) showed that there was a 
significant BOLD signal reduction in both the alcoholminus and alcoholplus groups 
(p<0.05 - Fig 2B) compared to the control group. There was also a main effect 
of group in the left (F=4.17; df=2, 78; p<0.05) and right (F=4.12; df=2, 78; 
p<0.05) ventral caudate/nucleus accumbens (NAcc) showing that the alcoholminus 
group (p<0.05), and to a greater degree, the alcoholplus group (p<0.01) 
exhibited a significantly lower BOLD signal change than the control group across 
these striatal regions (Fig 3A & 3B).  
-Insert Figure 2 about here- 
-Insert Figure 3 about here- 
Additionally, there was a significant effect of group in the right frontal pole 
cluster (F=6.23; df=2, 78; p<0.05 - alcoholminus<control, p<0.05; 
alcoholplus<control, p<0.01); right cerebellum cluster (F=3.5; df=2, 78; p<0.05 
- alcoholplus<control, p<0.05); right parahippocampal gyrus cluster (F=6.40; 
df=2, 78; p<0.01 - alcoholminus<control, p<0.05; alcoholplus<control, p<0.01); 
right supramarginal gyrus cluster (F=4.10; df=2, 78; p<0.05 - alcoholminus and 
alcoholplus<control, p<0.05); left middle temporal gyrus/parahippocampal gyrus 
cluster (F=7.73; df=2, 78; p<0.01 - alcoholminus<control, p<0.05; 
alcoholplus<control, p<0.001) and the left occipital fusiform gyrus cluster 
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(F=3.32; df=2, 78; p<0.05 - alcoholplus<control, p<0.05). We did not, however, 
observe a significant effect of group in either the left (F=2.21; df=2, 78; p<0.1) 
or right (F=2.25; df=2, 78; p<0.09) anterior cingulate cortex (ACC) clusters, 
suggesting that the original observed group effect in this region was due to a 
conflation of the alcoholminus and alcoholplus groups. In order to confirm this, we 
collapsed across the two groups and conducted a Two (Group: alcoholminus & 
alcoholplus combined vs. control) by two (Drug: placebo vs. naltrexone) repeated 
measures ANOVA to verify a significant effect of group in the left (F=4.88; df=1, 
79; p<0.5 - alcoholminus & alcoholplus combined<control - Fig 4A), and right 
(F=5.06; df=1, 79; p<0.5 - alcoholminus & alcoholplus combined<control - Fig 4B) 
ACC clusters. 
-Insert Figure 4 about here- 
The same whole brain cluster-based repeated measures ANOVA analysis 
also revealed a significant main effect of group for the win miss>neutral miss 
contrast in the left insula (140 voxels; x=-42; y=14; z=-12; zF=3.72; df=1, 79; 
p<0.001) and the right ACC (415 voxels; x=4; y=44; z=4; zF=3.51; df=1, 79; 
p<0.001) only. As with the anticipation contrast, we additionally conducted the 
same three by two repeated measures ANOVA on the mean BOLD signal change 
within these two clusters. There was a significant effect of group in the left 
insula (F=4.51; df=2, 78; p<0.05 - alcoholminus and alcoholplus<control, p<0.05 - 
Fig 5A) and in the right ACC (F=4.21; df=2, 78; p<0.05 - alcoholminus and 
alcoholplus<control, p<0.05 - Fig 5B), showing that the alcoholminus and alcoholplus 
groups independently contributed main ANOVA group effect. This same analysis 
also showed a trend towards a drug effect in both the insula (F=2.87; df=1, 78; 
p=0.09) and ACC (F=3.13; df=1, 78; p=0.08) clusters, likely driven by the 
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direction of signal change on the naltrexone session in the alcoholminus and 
alcoholplus groups. Therefore, we additionally performed post hoc within group 
paired t-test analyses and showed that in the alcoholplus group only, there was a 
attenuation of the BOLD signal change during the naltrexone compared to the 
placebo session in both the insula (-t=2.12; df=24, p<0.05) and the ACC (-
t=2.26; df=24, p<0.05) clusters. There were no significant main effects for the 
win hit>neutral hit contrast. 
-Insert Figure 5 about here- 
Discussion 
This study set out to examine fronto-striatal activation during reward 
anticipation and instrumental responding in long-term abstinent alcoholic and 
alcoholic polysubstance-dependent individuals in order to evaluate the acute 
modulating effects of MOR blockade on these processes. The study showed that 
the alcoholplus group exhibited slower and less accurate instrumental responding 
across MID conditions compared to both the alcoholminus and control groups 
during the placebo session, an effect that was less evident after naltrexone but 
with no absolute improvement in speed and accuracy of responding as a result 
of drug treatment. The study additionally showed, however, that while there 
were no effects on the relative motivational value (RMV) for rewards, there were 
disturbances within fronto-striatal regions during reward anticipation and 
“missed” rewards in both substance dependent groups that were not reliably 
remediated by acute naltrexone treatment.  
The observed slower and less accurate responding of the alcoholplus group 
may suggest a low degree of motivation during the sustained cognitive demands 
of general instrumental effort. Using a behavioural motivational index that 
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specifically reflects a higher relative value for reward incentives during 
instrumental responding, however, we observed no difference between groups or 
any effects of naltrexone. The apparent remediation produced by acute 
naltrexone in the alcoholplus group seems most likely to be a consequence of 
changes in response to naltrexone in the comparison groups as there was little 
evidence of absolute improvements in behavioural functioning produced by 
naltrexone in the alcoholplus group. 
 
Reduced BOLD activation changes in the alcoholplus group 
Under conditions of reward anticipation, the alcoholplus group exhibited 
significantly lower activation change in the OFC compared with that of the 
control group across drug treatments. There is previous evidence of 
hypofunctioning in the OFC (London et al., 2000), particularly during abstinence 
(Volkow et al., 1992). The OFC  has important functional connections with the 
striatum (Volkow et al., 2000), and is known to code the motivational value of 
stimuli (Koeneke et al., 2008). The OFC also contains a high number of MOR 
(Gorelick et al., 2005), suggesting that any disturbance to the brain’s opioid 
system might be modulated by naltrexone. The current results, however, 
provide no evidence for an acute modulatory effect in the OFC, instead 
suggesting that disturbances within striato-orbitofrontal circuitry that subserves 
reward prediction and motivational processes, are sustained in long-term 
polysubstance, but not alcohol, abstinence.  
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Independent BOLD activation reductions in the alcoholminus and alcoholplus groups 
Compared to controls, the alcoholminus, and to a greater degree, the 
alcoholplus group, exhibited reduced bilateral ventral caudate/NAcc activation in 
response to the anticipation of potential monetary rewards. The current result 
concurs with previous research findings of altered striatal activity for non-drug 
rewards in substance dependence (Buhler et al., 2010; Bustamante et al., 2014; 
Diekhof et al., 2008; Gradin et al., 2014; Peters et al., 2011; Wrase et al., 
2007) and may be consistent with a sustained striatal reward deficiency 
syndrome (Blum et al., 2000; Koob et al., 2004) in long-term substance 
abstinence. There are also high levels of MORs in the caudate (Arvidsson et al., 
1995), making this region a credible target for modulation with naltrexone. The 
current findings, however, do not appear to support a remediating effect of 
naltrexone in this particular behavioural context. 
The current study also found that both the alcoholminus and alcoholplus 
groups demonstrated reduced activation changes compared with controls in the 
frontal pole and IFG/insula regions during reward anticipation. The PFC 
represents both cognitive and reward-related information processing (Watanabe 
et al., 2007), whereas the insula is implicated in reward and risk prediction 
(Preuschoff et al., 2008) and addiction relapse (Paulus et al., 2005; Seo et al., 
2013), possibly due to its role in awareness of interoceptive (i.e. bodily) states 
(Critchley et al., 2004). The current findings may, therefore, suggest that in 
long-term alcohol and polysubstance abstinence, there are sustained 
disturbances within a network of regions that function to integrate the cognitive 
interpretation of motivational drives (Goldstein et al., 2007) and other emotional 
and interoceptive states.   
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We also observed that the alcoholminus and alcoholplus groups exhibited 
reduced activation changes compared with controls in the anterior insula, and 
notably, the rostral ACC (rACC) during “missed” rewards. The rACC has been 
labelled as the “affective division” of the cingulate (Bush et al., 2000; Devinsky 
et al., 1995), through processing the emotional components of errors (Luu et al., 
2003; van Veen et al., 2002). The observed decrease in error-related rACC and 
insula activation may have resulted from decreases in arousal during misses, an 
effect that was apparently exacerbated by acute opioid blockade with 
naltrexone. This blunting of error-related signalling by naltrexone in substance 
abusers may have clinical implications, where arousal and conflict monitoring are 
necessary responses to violations in prediction that require adjustments to 
ongoing behaviour during treatment.  The effects of naltrexone in the insula and 
ACC, however, may encourage further investigations regarding the effects of 
opioid blockade on error-related neural responses in addiction populations. 
        
Interdependent BOLD activation reductions in the alcoholminus and alcoholplus 
groups 
 
When combined, the alcoholminus and alcoholplus groups exhibited reduced 
activations in the ACC during the anticipation of monetary reward compared to 
controls that were not modulated by naltrexone. The ACC has been implicated in 
addiction and its cognitive sequelae (Goldstein et al., 2002; Peoples, 2002; 
Volkow et al., 2002), with disturbances in this region reported in a number of 
abstinent substance abusing populations (Bolla et al., 2004; Eldreth et al., 2004; 
Nestor et al., 2011; Salloum et al., 2007). One of these differences was 
observed for the caudal dorsal ACC (cdACC), a region involved in processing the 
value of actions, motivation and expected outcomes under conditions of reward 
(Kouneiher et al., 2009). This may suggest that neural processing within a 
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motivational and reward prediction cognitive network remains compromised in 
long-term substance abstinence.  
 
Limitations of the current study include a lack of complete matching of 
groups with respect to age, cannabis and cigarette use, anxiety and mood 
measures, which means we cannot unequivocally dismiss their potential 
influence on altered reward processing in fronto-striatal circuitry of both the 
alcoholminus and alcoholplus groups. Furthermore, we did not thoroughly assess 
alcohol and drug craving at each session across the groups, which may have had 
a possible influence on our metrics of motivation and reward processing. 
Moreover, dependence on (and abstinent from) multiple and varying substances 
of abuse in the alcoholplus group underpowered us to statistically examine the 
influence of these measures on indices of motivation and reward processing. 
While our groups were well matched on the distribution of gender, the small 
number of females in each group did not permit us to examine the influence of 
gender effects on the neurobiology of reward and motivational processes in the 
two substance-dependent groups.  The reduced number of loss trials in our MID 
task also meant we were unable to examine the neural correlates of loss 
anticipation and outcome, where sensitivity to punishment may well have 
implications for treatment and drug relapse. 
 
In summary, the current study set out to map the impact of MOR 
blockade upon neural networks disrupted in substance dependence and has 
demonstrated evidence of sustained disturbances within fronto-striatal regions of 
long-term abstinent alcoholics and polysubstance-dependent individuals. It has 
also shown that acute naltrexone treatment produced a relative minor 
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amelioration of behavioural performance on a monetary delayed incentive task 
in an alcoholic, polydrug abuser group (alcoholplus), but not in a group of patients 
with “pure” alcoholic abuse (alcoholminus). Moreover, naltrexone was unable to 
reverse neural changes in fronto-striatal systems associated with the MID task, 
possibly suggesting the potential insensitivity of this task for elucidating possible 
therapeutic effects on neural biomarkers in future experimental medicine 
studies.  
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Figure 1. MID task performance in the alcoholminus, alcoholplus and control groups 
during the placebo and naltrexone sessions for A) mean percentage accuracy; B) 
mean reaction time and C) relative motivational value (RMV). Accuracy and 
reaction time data were analyzed using a three (Group: alcoholminus vs. alcoholplus 
vs. control) by two (Drug: placebo vs. naltrexone) by two (Condition: neutral vs. 
win) repeated measures ANOVA. RMV was analysed using a three (Group: 
alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo vs. naltrexone) 
repeated measures ANOVA. MID accuracy: •••p<0.001 - Win>Neutral; **p<0.01 
- alcoholplus<control on placebo; ***p<0.001 - alcoholplus<alcoholminus on 
placebo. MID reaction time: •••p<0.001 - Win<Neutral; *p<0.05 - 
alcoholplus<alcoholminus & control on placebo. Data are expressed as means ± 
SEM. 
 
Figure 2. Three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) repeated measures ANOVA on the mean BOLD signal 
change scores within the group ANOVA zF-statistic clusters for the win 
anticipation>neutral anticipation contrast. Results showed that the alcoholplus 
group had significantly less activation change in A) the left OFC compared to the 
control group (**p<0.01) and that the control group had significantly greater 
activation change in B) the right IFG/insula compared to both the alcoholminus and 
alcoholplus  groups (*p<0.05). Data are expressed as means ± SEM. Co-
ordinates are represented in Montreal Neurological Institute (MNI) space. OFC: 
orbitofrontal cortex; IFG: inferior frontal gyrus. 
 
Figure 3. Three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) repeated measures ANOVA on the mean BOLD signal 
change scores within the group ANOVA zF-statistic clusters for the win 
anticipation>neutral anticipation contrast. Results showed that the control group 
had significantly greater activation change in A) the right caudate/NAcc 
compared to both the alcoholminus (*p<0.05) and alcoholplus (**p<0.01) groups 
and in B) the left caudate/NAcc compared to both the alcoholminus (*p<0.05) and 
alcoholplus (**p<0.01) groups. Data are expressed as means ± SEM. Co-
ordinates are represented in Montreal Neurological Institute (MNI) space. NAcc: 
nucleus accumbens. 
 
Figure 4. Two (Group: alcoholminus & alcoholplus combined vs. control) by two 
(Drug: placebo vs. naltrexone) repeated measures ANOVA on the mean BOLD 
signal change scores within the group ANOVA zF-statistic clusters for the win 
anticipation>neutral anticipation contrast. Results showed that the control group 
had significantly greater activation change in A) the left anterior cingulate cortex 
(*p<0.05) and in B) the right anterior cingulate cortex (*p<0.05) compared to 
alcoholminus & alcoholplus combined. Data are expressed as means ± SEM. Co-
ordinates are represented in Montreal Neurological Institute (MNI) space. 
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Figure 5. Three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) repeated measures ANOVA on the mean BOLD signal 
change scores within the two group ANOVA zF-statistic clusters for the win 
miss>neutral miss contrast. Results showed that the control group had 
significantly greater activation change in A) the left insula (*p<0.05) and in B) 
the right anterior cingulate cortex (*p<0.05) compared to both the alcoholminus 
and alcoholplus groups. Within group analyses also revealed that the alcoholplus 
group had a greater BOLD signal reduction on naltrexone compared to placebo in 
both these regions (•p<0.05). Data are expressed as means ± SEM. Co-
ordinates are represented in Montreal Neurological Institute (MNI) space. 
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Table 1. Demographic variables for the control, alcoholminus and alcoholplus groups. Age *p<0.05 - alcoholminus>alcoholplus & 
control; Edu **p<0.01 - alcoholplus<control; IQ *p<0.05 - alcoholplus<control; Alcohol Exposure ***p<0.001 
control<alcoholminus & *p<0.05 - alcoholplus<alcoholminus; Cigarette Use **p<0.01 - alcoholplus>control; Cannabis Use 
***p<0.001 - alcoholplus>alcoholminus & control. Also shown are the months of abstinence from alcohol in all three groups and 
additional substances of dependence in the alcoholplus group. Data are expressed as means ± SEM. Ranges of substance 
asbtinence are also provided in parentheses.  
 
      Control (n=35) AlcoholMinus (n=21) AlcoholPlus (n=25) 
Gender (Female/Male)     7/28      4/17  6/19 
Age   41.11 ± 1.54     46.23 ± 1.96*                    39.60 ± 1.52 
Edu   13.45 ± 0.45   12.66 ± 0.65    11.32 ± 0.42** 
IQ 105.91 ± 1.71 105.28 ± 1.82  99.36 ± 2.39* 
Handedness   46.08 ± 9.75     55.74 ± 14.12  62.91 ± 11.22 
Alcohol Exposure (yrs)          0.80 ± 0.44***   18.71 ± 1.88  13.42 ± 1.94* 
Cigarette Use (pack yrs)     9.99 ± 2.11   17.44 ± 4.45    22.27 ± 3.31** 
Cannabis Use (yrs)     0.34 ± 0.34     2.80 ± 1.05       8.64 ± 1.78*** 
Alcohol Abstinence (mths)           0.34 ± 0.2 (5.0)            14.08 ± 4.23 (78.5)          13.69 ± 2.50 (34.5) 
Cocaine Abstinence (mths)    -     -          24.10 ± 4.86 (82.5) 
Opiate Abstinence (mths)    -     -           39.47 ± 14.75 (274) 
Amphetamine Abstinence (mths)    -     -         156.85 ± 51.48 (306) 
Benzodiazepine Abstinence (mths)    -     -              64.50 ± 51.87 (161.5) 
GHB Abstinence (mths)    -     -        36.0 ± 0.00 (0) 
Solvent Abstinence (mths)    -     -      396.0 ± 0.00 (0) 
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Table 2. ANOVA group effect clusters from a two (Group: alcoholminus & alcoholplus combined vs. control) by two (Drug: 
placebo vs. naltrexone) whole-brain cluster-based repeated measures ANOVA for the win anticipation>neutral anticipation 
contrast. Statistical images were first thresholded using clusters determined by Z>2.3 with a corrected cluster significance 
level of p<0.05. The P value corresponding to the maximum zF-statistic within each cluster is shown. Co-ordinates are 
represented in Montreal Neurological Institute (MNI) space.  
      
Voxel 
Cluster Region Voxels p value HS x(mm) y(mm) z(mm) zF-Stat 
 
Occipital Fusiform Gyrus 798 <0.0001 L -46 -66 -20 6.41 
Inferior Frontal Gyrus/Insula 351 <0.0001 R 52 16 -2 4.56 
Middle Temporal/Parahippocampal Gyrus 324 <0.0001 L -60 -14 -16 3.72 
Supramarginal Gyrus 319 <0.0001 R 68 -34 36 3.47 
Parahippocampal Gyrus 228 <0.001 R 36 -28 -14 4.37 
Caudate/Nucleus Accumbens 214 <0.01 L -8 14 -2 3.65 
Cerebellum 194 <0.01 R 22 -46 -24 3.36 
Anterior Cingulate Cortex 192 <0.01 L -1 -8 32 4.08 
Anterior Cingulate Cortex 182 <0.01 R 6 18 28 4.22 
Caudate/Nucleus Accumbens 162 <0.01 R 10 10 4 3.45 
Frontal Pole 155 <0.05 R 20 58 -8 4.10 
Orbitofrontal Cortex 147 <0.05 L -30 32 -14 5.04 
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